UK Markets closed

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of DBV Technologies S.A. Investors (DBVT)


Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased DBV Technologies S.A. (NASDAQ: DBVT) (“DBV Technologies” or the “Company”) securities between October 22, 2018 and December 19, 2018, inclusive (the “Class Period”). DBV Technologies investors have until March 18, 2019 to file a lead plaintiff motion.

On December 19, 2018, DBV Technologies revealed that, following discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut was voluntarily withdrawn. According to the Company, the FDA communicated that “the level of detail with regards to data on manufacturing and quality controls was insufficient in the BLA.” On this news, DBV Technologies’ share price fell $8.39, or nearly 60%, to close at $5.76 on December 20, 2018, thereby injuring investors.

The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) DBV Technologies’ BLA for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies would have to withdraw their BLA for Viaskin Peanut; and (3) as a result, defendants’ statements about DBV Technologies’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

If you purchased shares of DBV Technologies, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to, or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on